Glycophospholipid Formulation with NADH and CoQ10 Significantly Reduces  Intractable Fatigue in Western Blot-Positive ‘Chronic Lyme Disease’  Patients: Preliminary Report by Garth L. Nicolson et al.
Functional Foods in Health and Disease 2012, 2(3):35-47                                                                    Page 35 of 47 
 
Research Article                                                                                                         Open Access  
 
  Glycophospholipid Formulation with NADH and CoQ10 Significantly Reduces 
Intractable Fatigue in Western Blot-Positive ‘Chronic Lyme Disease’ 
Patients: Preliminary Report 
 
Garth L. Nicolson,
1* Robert Settineri,
2and
  Rita Ellithorpe
3 
 
1Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, 
California  92647,  USA; 
2Sierra  Research,  Irvine,  California  92606,  USA; 
3Tustin  Longevity 
Center, Tustin, California 92780, USA 
 
*Corresponding  author:  Prof.  Garth  L.  Nicolson,  Office  of  the  President,  The  Institute  for 
Molecular Medicine, P.O. Box 9355, S. Laguna Beach, CA 92652, USA 
 
Submission date: February 14, 2011, Acceptance date: March 27, 2011; Publication date: March 
28, 2012 
 
 
Abstract    
Background: An open label 8-week preliminary study was conducted in a small number of 
patients  to  determine  if  a  combination  oral  supplement  containing  a  mixture  of 
phosphoglycolipids,  coenzyme Q10 and microencapsulated NADH and other nutrients  could 
affect fatigue levels in long-term, Western blot-positive, multi-symptom „chronic Lyme disease‟ 
patients (also called „post-treatment Lyme disease‟ or „post Lyme syndrome‟) with intractable 
fatigue.  
 
Methods: The subjects in this study were 6 males (mean age = 45.1 ± 12.4 years) and 10 females 
(mean age = 54.6 ± 7.4 years) with „chronic Lyme disease‟ (determined by multiple symptoms 
and  positive  Western  blot  analysis)  that  had  been  symptomatic  with  chronic  fatigue  for  an 
average of 12.7 ± 6.6 years.  They had been seen by multiple physicians (13.3 ± 7.6) and had 
used many other remedies, supplements and drugs (14.4 ± 7.4) without fatigue relief.  Fatigue 
was monitored at 0, 7, 30 and 60 days using a validated instrument, the Piper Fatigue Scale. 
 
Results:  Patients  in  this  preliminary  study  responded  to  the  combination  test  supplement, 
showing a 26% reduction in overall fatigue by the end of the 8-week trial (p< 0.0003).  Analysis 
of subcategories of fatigue indicated that there were significant improvements in the ability to 
complete tasks and activities as well as significant improvements in mood and cognitive abilities.  
Regression analysis of the data indicated that reductions in fatigue were consistent and occurred 
with a high degree of confidence (R
2 = 0.998).  
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Conclusions:  The  combination  supplement  was  a  safe  and  effective  method  to  significantly 
reduce  intractable  fatigue  in  long-term  patients  with  Western  blot-positive  „chronic  Lyme 
disease.‟ 
 
Keywords:  Lyme  disease,  Lipid  Replacement  Therapy,  NT  Factor,  mitochondria,  chronic 
fatigue, NADH, coenzyme Q10 
 
 
BACKGROUND: 
„Chronic  Lyme  disease‟  (sometimes  called  „post-Lyme  syndrome‟  or  „post-treatment  Lyme 
disease syndrome‟) is a heterogeneous, chronic, systemic, multi-symptom illness resulting from 
the  tick-borne  infection  of  the  spirochete  Borrelia  burgdorferi  and  associated  co-infections 
(Mycoplasma species, Bartonella species, Babesia species, etc.) [1-3].  Although the early stages 
of this complex infection are widely recognized and routinely treated, there are controversies 
surrounding  the  diagnosis  and  treatment  of  advanced  multi-symptom  „post-Lyme  disease 
syndrome,‟ „post-treatment Lyme disease syndrome‟ or „chronic Lyme disease‟ [2-4].  One of 
the most common symptoms is chronic fatigue [2, 4, 5], and some patients with „chronic Lyme 
disease‟ are initially diagnosed with another fatiguing illness, chronic fatigue syndrome (CFS) 
[6,  7].    Like  „chronic  Lyme  disease,‟  CFS  is  also  characterized  by  multiple  symptoms  and 
chronic infections [7-10], and chronic fatigue is one of the most characteristic symptoms in both 
of these chronic illnesses [2, 4-7, 9].   
 
INTRODUCTION: 
Natural  supplements  have  been  used  to  reduce  fatigue  in  patients  with  a  variety  of  chronic 
illnesses [11, 12].  Few of these natural supplements were, however, considered effective [12].  
Chronic or intractable fatigue that is not reversed by sleep is the most common complaint of 
patients seeking general medical care [13, 14].  Fatigue is quite common; it occurs naturally 
during aging and in many chronic conditions [14].   
Fatigue has been described as a multidimensional sensation, and clinical studies have 
determined the extent of chronic fatigue in aging and in various medical conditions [13, 15-17].  
Fatigue is perceived to be a loss of overall energy and inability to perform even simple tasks 
without exertion [13, 14].   At the cellular level fatigue is related to cellular energy systems 
found  primarily  in  the  cellular  mitochondria  and  specifically  in  the  inner  mitochondrial 
membrane  electron  transport  chain  [18,  19].    Damage  to  mitochondrial  membranes  occurs 
mainly  by  oxidation,  and  this  can  result  in  increased  ion  leakage  across  mitochondrial 
membranes and impairment in the ability of mitochondria to produce high-energy molecules.  
Other cellular membranes are also affected by oxidation, resulting in impaired function [20, 21].   
Damage  to  cellular  membranes  occurs  mainly  due  to  the  production  of  free-radical 
oxidative  molecules,  such  as  reactive  oxygen  and  nitrogen  species  (ROS/RNS).    ROS/RNS 
include nitric oxide, oxygen and hydroxide radicals and other molecules that can cause oxidative 
stress and cellular damage, especially to sensitive membrane phospholipids, proteins and DNA 
[20-23].    Important  targets  of  ROS/RNS  damage  are  cellular  membranes,  and  in  particular, 
mitochondrial  membranes,  especially  their  phospholipid  components  [21-24].    In  fatiguing Functional Foods in Health and Disease 2012, 2(3):35-47                                                                    Page 37 of 47 
 
illnesses,  such  as  CFS,  patients  show  excess  oxidative  stress  and  increased  susceptibility  to 
peroxidation of membrane lipids [25, 26].  To some degree this excess oxidative stress can be 
reduced with antioxidant supplements [27-29], but these antioxidants cannot repair the oxidative 
damage done to cells.  Thus supplements have been developed that contain unoxidized precursor 
molecules that can repair and prevent damage to cellular membranes. 
  Recent clinical trials have shown the effectiveness of lipid replacement therapy (LRT) 
plus antioxidants in the treatment of CFS and related conditions [16, 30].  LRT results in the 
actual replacement  of damaged cellular lipids  with  undamaged (unoxidized) lipids  to  ensure 
proper function of cellular structures, mainly cellular and organelle membranes.  LRT can result 
in the cellular delivery  of unoxidized, undamaged membrane glycophospholipids in order to 
replace damaged lipids and restore function to oxidized cellular membranes. 
  Here we tested the results of using a formulation of glycophospholipids, CoQ10 plus 
microencapsulated NADH and other nutrients on suppression of fatigue during an open label 
two-month trial.  The subjects in this study were „chronic Lyme disease‟ patients defined as 
Lyme Western blot-positive patients with long-term intractable fatigue and other symptoms that 
had tried unsuccessfully many drugs and supplements to reduce their fatigue.   
 
SUBJECTS AND METHODS: 
Methods. An open label, institutionally approved clinical trial was initiated to study the effects 
of an all-natural supplement on fatigue in patients with Western blot-positive „chronic Lyme 
disease.‟  The  supplement  product,  ATP  Fuel®,  containing  NT  Factor®,  microencapsulated 
NADH,  CoQ10,  pro-  and  pre-biotics  and  other  nutrients  (Researched  Nutritionals,  Inc.,  Los 
Olivos, CA), is a patent-pending proprietary nutrient complex containing an exogenous source of 
polyunsaturated  phosphatidylcholine,  phosphatidylglyerol,  phosphatidylserine, 
phosphatidylinositol, and other membrane phospholipids, as well as coenzyme Q10 (CoQ10), 
microencapsulated reduced nicotinamide adenine dinucleotide (NADH) and other micronutrients 
(Table 1). The participants took the suggested daily dose (5 capsules in the morning and 5 at 
night) for 8 weeks.  
 
 
Table 1.  Test Supplement (ATP Fuel® with NT Factor®, NADH and CoQ10)
a 
______________________________________________________________________________ 
                Amount        % 
                   Per        Daily 
Component              Serving
b      Value
c 
______________________________________________________________________________ 
 
Vitamin E (as alpha-D-tocopheryl)            20 IU      67 
 
Krebs Energy Foundation
TM              35 mg      * 
     NADH, Coenzyme Q10 
 
Mitochondria Pro Regulator
TM           260 mg
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    Calcium (as calcium pyruvate, calcium ascorbate  
    dicalcium phosphate), phosphate/sulfate/pyruvate;  
    Phosphorus (as dicalcium phosphate); 
    Magnesium (as magnesium oxide) 
     
Krebs Cycle Glucose Absorb
TM          180 mg      * 
    Alpha-ketoglutaric acid, L-tyrosine 
 
RN Fatty Acid Metabolizer
TM          160 mg      * 
    L-carnitine L-tartrate, pantethine 
 
NT Factor®
e Maximum Potency
TM                2,000 mg      *   
______________________________________________________________________________ 
aATP Fuel® is a registered trademark of Researched Nutritionals, Inc., Los Olivos, CA.
 
bOne Serving = 5 capsules; total protein per serving = 0.7 g.  Total calories per serving = 9.5; 2.5 
calories per serving from unsaturated lipids.  Daily dose = 2 servings
 
cDaily values are based on a 2,000 calorie per day diet. 
dPer serving: calcium 136 mg, iron 40 mcg, phosphorus 48 mg, magnesium 43 mg, manganese 
10 mcg, potassium 9.5 mg 
eNT  Factor®  is  a  nutrient  complex  containing  membrane  polyunsaturated  phospholipids 
extracted  from  soy  lipids  and  purified  using  proprietary  processes,  Bifido  and  Lactobacillus 
bacteria with supportive essential growth media and phytonutrients for optimal absorption and 
performance, by Nutritional Therapeutics, Inc., Commack, NY.  
*Daily values not established 
 
 
Fatigue was scored using the validated Piper Fatigue Scale (PFS) [30-32].  The PFS is composed 
of 22 numerically scaled questions rated from 0 (no fatigue) to 10 (severe fatigue) [31, 32].  
These  items  measure  four  dimensions  of  subjective  fatigue:    behavioral/severity  (6  items); 
affective/meaning (5 items); sensory (5 items); and cognitive/mood (6 items).  These are used to 
calculate the four sub-scale/dimensional scores and the total fatigue scores.  The standardized 
alpha (Cronbach‟s alpha) coefficient of reliability did not drop below 0.99 for any of the subscale 
data, and the standard alpha for the entire scale of 22 questions was 0.98, indicating excellent 
reliability and internal consistency for this established instrument [33]. The study participants 
took the PFS survey at days 0, 7, 30 and 60.
 
 
Subjects.  Participants were prescreened after an initial contact to determine whether they could 
have „chronic Lyme disease‟ [34].  Subjects were included in the trial if they had been ill for at 
least  6  months,  had  a  multi-symptom  chronic  condition  characterized  by  several  signs  and 
symptoms,  such  as  intractable  fatigue,  joint  and  muscle  pain  (arthralgia),  muscle  aches 
(myalgia),  memory  impairment  and  other  symptoms  [34],  and  they  or  their  physician  could 
provide Western blot evidence for Lyme disease Borrelia burgdorferi infection [2, 7, 34].  This 
was defined as at least three bands positive in the Borrelia Western blot.  Those who qualified Functional Foods in Health and Disease 2012, 2(3):35-47                                                                    Page 39 of 47 
 
completed an  Informed Consent document and PFS on-line evaluation [30-32].  Participants 
were also asked how long their condition existed, whether it had been affected by any drug or 
supplement, and how many physicians they had been to before entering the trial.  They were also 
asked if they were currently using any prescription medications to see if this might exclude them 
from the study, as determined previously [30, 35].  The completed online surveys were scored as 
described previously [35, 36]. 
There were 16 respondents (10 females and 6 males) who met the criteria of chronic 
Lyme  disease  and  were  fully  compliant  and  completed  the  study.    The  mean  age  ±  SD  of 
participants completing the study was 52.4 ± 10.8 (females, 54.6 ± 7.4 years and males, 45.1 ± 
12.4 years, respectively).   
 
Study  Design.  Each  participant  was  given  instructions  to  take  the  glycophospholipid 
supplement with NADH and CoQ10 daily after an initial PFS assessment (time 0). All subjects 
repeated the PFS assessment at the end of the first week on line without access to their previous 
scores.  After the participants completed their PFS questionnaires at 30 and 60 days, all of the 
electronic  forms  were  checked  for  verification,  completion  and  scoring  accuracy  [36].  
Compliance was determined by counting the remaining capsules left over by each participant in 
the study.
 
 
Statistics.  Data were analyzed by ANOVA, with significance defined as p<0.05.  Further data 
analysis was performed with Tukey test and linear regression analysis, with significance defined 
as  p<0.05.  The  standardized  alpha  (Cronbach‟s  alpha)  was  used  to  confirm  reliability  and 
internal consistency of the data [33].  
 
RESULTS: 
Subjects in the Study. The subjects in this study were Borrelia Western blot-positive, chronic 
disease patients  who had moderate to  severe chronic fatigue for  years without improvement 
(mean ± SD years without improvement of fatigue = 12.7 ± 6.6 years).   Most had been to 
multiple physicians (mean ± SD = 13.3 ± 7.6) and had taken a variety of remedies, drugs and 
supplements (mean ± SD = 14.4 ± 7.4) without expected relief of their fatigue symptoms.  Of the 
20 subjects that started the trial, 16 completed the study. Almost all of the subjects that withdrew 
from  the  study  did  so  without  ever  completing  the  day  0  PFS  survey  and  taking  the  test 
supplement, or they were omitted from the data analysis for non-compliance during the trial.  
 
Effects of the Test Supplement on Fatigue.  We examined the effects of the combination 
glycophospholipid-NADH-CoQ10 preparation used in this study (Table 1) on fatigue scores in a 
2-month open label trial and found significant improvements in the overall fatigue scores of the 
study subjects as measured by the PFS (Table 2).  The initial PFS group mean total fatigue score 
± SEM was 8.1 ± 1.4, and after 8 weeks of supplement this improved to 6.0 ± 1.2, or a 26% 
reduction in fatigue.  The mean decrease in fatigue scores was significant by t-test (p< 0.0003) 
and Wilcoxon signed-rank  (p< 0.0002) analyses. 
  The  PFS  can  be  further  dissected  into  subcategories  that  include:  behavior/severity, 
affective meaning, sensory and cognitive/mood (Table 2).  All of these subcategories showed Functional Foods in Health and Disease 2012, 2(3):35-47                                                                    Page 40 of 47 
 
significant  reductions  at  the  end  of  the  8-week  trial,  indicating  that  there  were  significant 
improvements in all subcategories of fatigue.  For example, there was a 26% reduction (p< 
0.005) in severity/behavior of fatigue, indicating that there was a significant reduction in the 
intensity of fatigue, and a significant increase in the ability to complete tasks, socialize and 
engaging in sexual and other activities.  Also, there was a 25% improvement (p< 0.010) in mood 
and cognitive ability, such as the ability to concentrate, remember and think clearly (Table 2).  
   
Table 2. Overall Fatigue and Subcategories of the Piper Fatigue Scale Survey 
______________________________________________________________________________
____ 
      Mean Fatigue Level ± S.E.M.               Percent  t-test   
Category    Day 0      Day 60             Reduction      
 
Overall Fatigue  8.1 ± 1.4    6.0 ± 1.2     26    p <0.0003 
       
Behavior/Severity
a  8.5 ± 1.7    6.3 ± 1.2    26    p <0.005   
 
Affective/Meaning
b  8.8 ± 1.6    7.0 ± 1.6    21    p <0.010 
 
Sensory
c    8.4 ± 1.2    6.2 ± 1.3    26    p <0.005 
 
Cognitive/Mood
d  7.0 ± 1.4    5.3 ± 1.2    25    p <0.010 
     
 
 
aBehavior/Severity  subcategory  deals  with  completing  tasks,  socializing,  engaging  in  sexual 
activity and other activities and intensity or degree of fatigue. 
bAffective/Meaning  subcategory  determines  whether  fatigue/tiredness  is  pleasant/unpleasant, 
patient is agreeable/disagreeable, protective/destructive, or feels normal/abnormal. 
cSensory subcategory determines whether patient is strong/weak, awake/sleepy, refreshed/tired, 
or energetic/unenergetic. 
dCognitive/Mood  subcategory  assesses  whether  patient  feels  relaxed/tense, 
exhilarated/depressed, able/unable to concentrate, remember and think clearly. 
 
Regression Analysis of Data.  To see if the trends in fatigue reduction over time during the trial 
were consistent, occurred with a high degree of confidence and could predict further reductions 
we conducted regression analyses of the data.  As shown in Figure 1, the regression analysis of 
overall  fatigue  in  each  of  the  subcategories  of  fatigue  (behavior/severity,  affective  meaning, 
sensory and cognitive/mood) indicated significant and consistent downward trends in the fatigue 
data (R
2 = 0.998), suggesting that further reductions in fatigue would have been likely if the trial 
had been continued (Figure 1).  The regression R
2 values for the various subcategories were: 
Behavior/severity, 0.999; Affective meaning, 0.998; Sensory, 0.998; and Cognitive/mood, 0.999.  Functional Foods in Health and Disease 2012, 2(3):35-47                                                                    Page 41 of 47 
 
Regression analysis of the overall fatigue yielded R
2 = 0.998.  This indicates a high level of 
confidence in the downward trends in all fatigue subcategories and total fatigue. 
 
            Days 
 
Figure 1.  Data regression analyses of Lyme disease patients taking the test supplement in a 60-
day trial.  X axis, days; Y axis, Piper Fatigue Score.  The regression R
2 values for the various 
subgroups were: 1: Behavior/severity, 0.999; 2: Affective meaning, 0.999; 3: Sensory, 0.998; and 
4: Cognitive/mood, 0.999.  Total: regression analysis of the overall fatigue, R
2 = 0.998. 
 
DISCUSSION: 
Lyme disease, the most common vector-borne infection in North America, is characterized by 
multiple signs and symptoms [1-3, 5, 34, 37].  Among the more commonly found symptoms are: 
joint and muscle pain (arthralgia), muscle aches (myalgia), memory impairment and fatigue [1, 
5, 34].  These symptoms overlap significantly with CFS, which may be why some Lyme disease 
patients are initially diagnosed with CFS [6, 7].  Although the treatment of the early stages of 
Lyme disease are relatively straight forward and involve short courses of antibiotics [2, 3, 34, 37, 
38], treatment of „chronic Lyme disease‟ has proven to be particularly difficult, lengthy and 
controversial,  involving  complex  regimens  of  antibiotics,  herbal  remedies,  nutritional 
supplements and rehabilitation [34, 39].  Use of nutritional supplements has been recommended 
in the supportive treatment of „chronic Lyme disease‟ [34, 39-41], but few if any clinical trials 
have examined the effectiveness of nutritional supplements on the signs and symptoms of Lyme 
disease [39]. 
Among the nutritional supplements suggested for the treatment of Lyme disease, omega-
3 fatty acids, CoQ10, L-carnitine and NT Factor® have been suggested [39, 41].  NT Factor® is Functional Foods in Health and Disease 2012, 2(3):35-47                                                                    Page 42 of 47 
 
of particular interest, since it has been used successfully in several animal and clinical studies 
[16, 22, 30, 35, 36, 43, 44].  In this formulation encapsulated lipids are protected from oxidation 
in  the gut  and can be absorbed and transported into tissues without oxidative damage.  NT 
Factor®  contains  a  variety  of  components,  including  phospholipids,  glycophospholipids  and 
other lipids, nutrients, probiotics, vitamins, minerals and other nutrients [22, 30, 35].
 
NT Factor® has been used in studies with severe chronic fatigued patients to reduce their 
fatigue [22, 30, 35, 43]. We found that fatigue was significantly reduced from severe to moderate 
fatigue, after eight weeks of supplementation with NT Factor® [30, 35, 43].  For example, use of 
NT Factor® for 12 weeks resulted in 35.5% reduction in fatigue (p< 0.001).  In this clinical trial 
there  were  good  correlations  between  reductions  in  fatigue  and  increases  in  mitochondrial 
function.  After 8 weeks of LRT with NT Factor®, mitochondrial function was significantly 
improved  (p<  0.001),  and  after  12  weeks  of  NT  Factor®  supplementation,  mitochondrial 
function  was  found  to  be  similar  to  that  of  young  healthy  adults  [43].    After  12  weeks  of 
supplement use, subjects were placed on placebo without their knowledge for an additional 12 
weeks, and their fatigue and mitochondrial function were again measured.  After the 12-week 
placebo cross-over period fatigue increased and mitochondrial function decreased, indicating that 
the NT Factor results on fatigue were not due to a “placebo effect” [43].  
  The dietary supplement we used was a preparation containing NT Factor®, CoQ10 and 
microencapsulated NADH.  Microencapsulated NADH alone had been found to have a positive 
effect on fatigue in some patients.  In one study a subset of patients responded or the response 
was for a limited period of time.  In a randomized, cross-over study on CFS patients 8 of 26 
(30.7%) responded to microencapsulated NADH compared to 2 of 26 (8%) on placebo (p< 0.05) 
[45].  These results were not considered significant by others [46, 47].  In a 24-month trial 
Santaella  et  al.  [35]  compared  the  effectiveness  of  oral  NADH  to  combination 
psychological/nutritional  therapy  in  31  CFS  patients.    They  found  that  NADH  resulted  in  a 
reduction in fatigue but only in the first trimester of the trial.  In subsequent trimesters, symptom 
scores were similar in the NADH and psychological/nutritional arms of the trial.  In another 
study oral NADH was given for two months to CFS patients.  In this study the NADH group 
showed a decrease in anxiety and maximum heart rate after a stress test compared to the placebo 
group, but differences were not found in the functional impact of fatigue, quality of life, sleep 
quality, exercise capacity or functional reserve [49].    
NADH is required as an important cofactor in many cellular enzyme pathways, including 
those involving certain  transferases,  polymerases,  synthases,  deacetylases  and other enzymes 
[50].    It  is  also  important  in  signal  transduction,  DNA  repair,  salvage  pathways  and  post-
translational protein modifications [51].  NADH in its reduced form is an important component 
of the mitochondrial electron transport chain, and it plays an important role in programmed cell 
death [52, 53].  
In the mitochondrial electron transport chain CoQ10 acts as an essential electron carrier, 
and it is also an important antioxidant as well as a molecule involved in gene regulation [54, 55].  
It has been used as an important supplement in a variety of chronic illnesses and age-related 
conditions [55-57].  In our studies CoQ10 was used to improve energy transduction and combat 
oxidative stress [55, 58], while CoQ10 has been used extensively for combined nutraceutical  
therapy in mitochondrial cytopathies [58, 59]. Functional Foods in Health and Disease 2012, 2(3):35-47                                                                    Page 43 of 47 
 
Here we used an all-natural formulation containing NT Factor®, CoQ10, NADH and 
other nutrients in „chronic Lyme disease‟ patients who had intractable chronic fatigue for an 
average of over 12 years.  Chronic fatigue is known to cause loss of mitochondrial function [59, 
60].  These patients had tried a large number of supplements and drugs (14.4 ± 7.4) with little or 
no effect on their fatigue.  Although these patients had intractable fatigue, they responded well to 
the combination supplement containing NT Factor®, CoQ10 and NADH.  Regression analysis 
indicated that the data  were consistent  and  reliable with  a high degree of confidence (R
2  = 
0.998).  The regression analysis further suggested that continuing the supplement beyond the 60 
days of the trial could result in further reductions in fatigue.   
Finally, the supplement was effective and safe for „chronic Lyme disease‟ patients.  This 
preliminary study should be repeated with a longer test period, a control arm and larger numbers 
of  fatigued  patients  with  other  chronic  illness  diagnoses.    Although  there  is  continuing 
controversy surrounding the evidence for chronic Borrelia infection in „chronic Lyme disease‟ or 
„post-treatment Lyme disease,‟ and the treatment of potential chronic infections [2-5, 34, 37, 61], 
there is general agreement that these patients have chronic fatigue symptoms  that should be 
addressed in any treatment strategy [34, 37, 41].  This preliminary study was only directed at 
reducing fatigue and cannot address other controversies surrounding „chronic Lyme disease‟ or 
„post-treatment Lyme disease‟ treatments [3, 37, 61]. 
 
CONCLUSIONS: 
After 60 days  use of a supplement containing a mixture of phosphoglycolipids,  CoQ10 and 
NADH, fatigue measured with the validated Piper Fatigue Scale was significantly reduced in 
patients  with  intractable  fatigue  and  Western  blot-positive  „chronic  Lyme  disease.‟    The 
supplement was safe and effective and for use in these patients, but the study should be repeated 
with larger numbers of patients for a longer period of time. 
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